The theoretical basis of transcriptional therapy of cancer: Can it be put into practice?

Journal of Clinical Oncology

Volumn 23, Issue 17, 2005, Pages 3957-3970

  Melnick, Ari M ^a   Adelson, Kerin ^a   Licht, Jonathan D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; SPLITOMYCIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE CONTROL; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; ANIMAL; FORECASTING; GENETICS; NEOPLASM; PHYSIOLOGY; PROMOTER REGION;

ANIMALS; DNA METHYLATION; FORECASTING; GENE SILENCING; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC;

EID: 21244481727     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.14.498     Document Type: Review

References (144)

1. Look AT: Oncogenic transcription factors in the human acute leukemias. Science 278: 1059-1064, 1997
2. Licht JD: AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 20:5660-5679, 2001
3. Dalla-Favera R, Migliazza A, Chang CC, et al: Molecular pathogenesis of B cell malignancy: The role of BCL-6. Curr Top Microbiol Immunol 246:257-263, 1999
4. Lodish H, Berk A, Zipursky L, et al: Molecular Cell Biology, 4th Edition. New York, W. H. Freeman, 2000
5. Lee TI, Young RA: Transcription of eukaryotic protein-coding genes. Annu Rev Genet 34: 77-137, 2000
6. Renaud JP, Rochel N, Ruff M, et al: Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378:681-689, 1995
7. Mayr B, Montminy M: Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2:599-609, 2001
8. Lin RJ, Nagy L, Inoue S, et al: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-814, 1998
9. Prive GG, Melnick A, Ahmad KF, et al: The BTB domain zinc finger proteins, in Shiro I, Kuldell N (eds): Zinc Finger Proteins: From Atomic Contact to Cellular Function. Georgetown, TX, Landes Biosciences/Eurekah.com, 2004 10. Urrutia R: KRAB-containing zinc-finger repressor proteins. Genome Biol 4:231, 2003
10. Melnick A, Licht JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215, 1999
11. Ye BH: The role of Bcl-6 in normal lymphoid system and non-Hodgkin's lymphomas, in Ravid K, Licht JD (eds): Transcription Factors: Normal and Malignant Development of Blood Cells. New York, John Wiley & Sons, 2001, pp 271-289
12. Melnick A, Carlile G, Ahmad KF, et al: Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with co-repressors. Mol Cell Biol 22:1804-1818, 2002
13. Ahmad KF, Melnick A, Lax S, et al: Mechanism of SMRT co-repressor recruitment by the BCL6 BTB domain. Mol Cell 12:1551-1564, 2003
14. Polo JM, Dell'oso T, Ranuncolo SM, et al: Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10:1329-1335, 2004
15. Yu J, Li Y, Ishizuka T, et al: A SANT motif in the SMRT co-repressor interprets the histone code and promotes histone deacetylation. EMBO J 22:3403-3410, 2003
16. Schultz DC, Ayyanathan K, Negorev D, et al: SETDB1: A novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev 16:919-932, 2002
17. Schultz DC, Friedman JR, Rauscher FJ 3rd: Targeting histone deacetylase complexes via KRAB-zinc finger proteins: The PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD. Genes Dev 15:428-443, 2001 19. Zheng L, Pan H, Li S, et al: Sequence-specific transcriptional co-repressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell 6:757-768, 2000
18. Hennemann H, Vassen L, Geisen C, et al: Identification of a novel Kruppel-associated box domain protein, Krim-1, that interacts with c-Myc and inhibits its oncogenic activity. J Biol Chem 278:28799-28811, 2003
19. Grant PA, Berger SL: Histone acetyltransferase complexes. Semin Cell Dev Biol 10:169-177, 1999
20. Sobulo OM, Borrow J, Tomek R, et al: MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA 94:8732-8737, 1997
21. Chaffanet M, Gressin L, Preudhomme C, et al: MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer 28:138-144, 2000
22. Wolffe AP, Urnov FD, Guschin D: Co-repressor complexes and remodelling chromatin for repression. Biochem Soc Trans 28:379-386, 2000
23. Jones PL, Shi YB: N-CoR-HDAC co-repressor complexes: Roles in transcriptional regulation by nuclear hormone receptors. Curr Top Microbiol Immunol 274:237-268, 2003
24. Davis JN, McGhee L, Meyers S: The ETO (MTG8) gene family. Gene 303:1-10, 2003
25. Friedman JR, Fredericks WJ, Jensen DE et al: KAP-1, a novel co-repressor for the highly conserved KRAB repression domain. Genes Dev 10:2067-2078, 1996
26. Urnov FD, Wolffe AP: Chromatin remodeling and transcriptional activation: The cast (in order of appearance). Oncogene 20:2991-3006, 2001
27. Nusinzon I, Horvath CM: Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci U S A 100:14742-14747, 2003
28. Taunton J, Hassig CA, Schreiber SL: A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272:408-411, 1996
29. Ng HH, Bird A: Histone deacetylases: Silencers for hire. Trends Biochem Sci 25: 121-126, 2000
30. Kuo MH, Allis CD: In vivo cross-linking and immunoprecipitation for studying dynamic Protein: DNA associations in a chromatin environment. Methods 19:425-433, 1999
31. Gray SG, Ekstrom TJ: The human histone deacetylase family. Exp Cell Res 262:75-83, 2001
32. Melnick A, Licht JD: Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 9:322-332, 2002
33. Gregoretti IV, Lee YM, Goodson HV: Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol 338:17-31, 2004
34. Gao L, Cueto MA, Asselbergs F, et al: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277:25748-25755, 2002
35. de Ruijter AJ, van Gennip AH, Caron HN, et al: Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 370:737-749, 2003
36. Hubbert C, Guardiola A, Shao R, et al: HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458, 2002
37. Zhang Y, Li N, Caron C, et al: HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22:1168-1179, 2003
38. Guarente L: Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 14:1021-1026, 2000
39. Langley E, Pearson M, Faretta M, et al: Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21:2383-2396, 2002
40. Motta MC, Divecha N, Lemieux M, et al: Mammalian SIRT1 represses forkhead transcription factors. Cell 116:551-563, 2004
41. Bereshchenko OR, Gu W, Dalla-Favera R: Acetylation inactivates the transcriptional represser BCL6. Nat Genet 32:606-613, 2002
42. Fujita N, Jaye DL, Geigerman C, et al: MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 119:75-86, 2004
43. Jenuwein T, Allis CD: Translating the histone code. Science 293:1074-1080, 2001
44. Berger SL: Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12: 142-148, 2002
45. Schreiber SL, Bernstein BE: Signaling network model of chromatin. Cell 111:771-778, 2002
46. de la Cruz X, Lois S, Sanchez-Molina S, et al: Do protein motifs read the histone code? Bioessays 27:164-175, 2005
47. Yang XJ: Lysine acetylation and the bromodomain: A new partnership for signaling. Bioessays 26:1076-1087, 2004
48. Tamaru H, Selker EU: A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414:277-283, 2001
49. Jenuwein T: Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol 11:266-273, 2001
50. Nakayama J, Rice JC, Strahl BD, et al: Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 292:110-113, 2001
51. Santos-Rosa H, Schneider R, Bernstein BE, et al: Methylation of histone H3 K4 mediates association of the Iswlp ATPase with chromatin. Mol Cell 12:1325-1332, 2003
52. Zegerman P, Canas B, Pappin D, et al: Histone H3 lysine 4 methylation disrupts binding of nucleosome remodeling and deacetylase (NuRD) represser complex. J Biol Chem 277: 11621-11624, 2002
53. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629, 2002
54. Chesi M, Nardini E, Lim RS, et al: The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92: 3025-3034, 1998
55. Sims RJ 3rd, Nishioka K, Reinberg D: Histone lysine methylation: A signature for chromatin function. Trends Genet 19:629-639, 2003
56. Shi Y, Lan F, Maison C, et al: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941-953, 2004
57. Langst G, Becker PB: ISWI induces nucleosome sliding on nicked DNA. Mol Cell 8:1085-1092, 2001
58. Fan HY, He X, Kingston RE, et al: Distinct strategies to make nucleosomal DNA accessible. Mol Cell 11:1311-1322,2003
59. Zhang Y, Ng HH, Erdjument-Bromage H, et al: Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 13: 1924-1935, 1999
60. Becker PB, Horz W: ATP-dependent nucleosome remodeling. Annu Rev Biochem 71: 247-273, 2002
61. Lund AH, van Lohuizen M: Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 16:239-246, 2004
62. van Lohuizen M, Verbeek S, Scheijen B, et al: Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65:737-752, 1991
63. Kim JH, Yoon SY, Kim CN, et al: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203: 217-224, 2004
64. Bea S, Tort F, Pinyol M, et al: BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409-2412, 2001
65. Vonlanthen S, Heighway J, Altermatt HJ, et al: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84:1372-1376, 2001
66. Jacobs JJ, Kieboom K, Marino S, et al: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164-168, 1999
67. Francis NJ, Kingston RE, Woodcock CL: Chromatin compaction by a polycomb group protein complex. Science 306:1574-1577, 2004
68. Herman JG, Civin Cl, Issa JP, et al: Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57:837-841, 1997
69. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428, 2002
70. Rountree MR, Bachman KE, Baylin SB: DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 25:269-277, 2000
71. Feng Q, Zhang Y: The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev 15:827-832, 2001
72. Fuks F, Hurd PJ, Wolf D, et al: The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278: 4035-4040, 2003
73. Bachman KE, Park BH, Rhee I, et al: Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3:89-95, 2003
74. Maison C, Almouzni G: HP1 and the dynamics of heterochromatin maintenance. Nat Rev Mol Cell Biol 5:296-304, 2004
75. Taddei A, Roche D, Sibarita JB, et al: Duplication and maintenance of heterochromatin domains. J Cell Biol 147:1153-1166, 1999
76. Kondo Y, Shen L, Issa JP: Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23: 206-215, 2003
77. Cameron EE, Bachman KE, Myohanen S, et al: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107, 1999
78. Kondo Y, Issa JP: Epigenetic changes in colorectal cancer. Cancer Metastasis Rev 23:29-39, 2004
79. Eads CA, Nickel AE, Laird PW: Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmtl-hypomorphic Mice. Cancer Res 62:1296-1299, 2002
80. Laird PW, Jackson-Grusby L, Fazeli A, et al: Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197-205, 1995
81. Trinh BN, Long TI, Nickel AE, et al: DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol Cell Biol 22:2906-2917, 2002
82. Di Croce L, Raker VA, Corsaro M, et al: Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079-1082, 2002
83. Zhu J, Gianni M, Kopf E, et al: Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci U S A 96:14807-14812, 1999
84. Shi Y: Mammalian RNAi for the masses. Trends Genet 19:9-12, 2003
85. Downward J: RNA interference. BMJ 328:1245-1248, 2004
86. Volpe TA, Kidner C, Hall IM, et al: Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science 297: 1833-1837, 2002
87. Lippman Z, Martienssen R: The role of RNA interference in heterochromatic silencing. Nature 431:364-370, 2004
88. Chevallier N, Corcoran CM, Lennon C, et al: ETO protein of t(8;21) AML is a co-repressor for Bcl-6 B-cell lymphoma oncoprotein. Blood 103:1454-1463, 2004
89. Chen Z, Brand NJ, Chen A, et al: Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 12: 1161-1167, 1993
90. Ye BH, Lista F, Lo Coco F, et al: Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large- cell lymphoma. Science 262:747-750, 1993
91. Chen WY, Zeng X, Carter MG, et al: Heterozygous disruption of Hid predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 33:197-202, 2003
92. Batlle E, Sancho E, Franci C, et al: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2:84-89, 2000
93. Hajra KM, Chen DY, Fearon ER: The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 62:1613-1618, 2002
94. Golub TR, Barker GF, Bohlander SK, et al: Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 92:4917-4921, 1995
95. Huynh KD, Bardwell VJ: The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 17:2473-2484, 1998
96. Melnick AM, Westendorf JJ, Polinger A, et al: The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a co-repressor for the promyelocytic leukemia zinc finger protein. Mol Cell Biol 20:2075-2086, 2000
97. Liu X, Sun Y, Weinberg RA, et al: Ski/Sno and TGF-beta signaling. Cytokine Growth Factor Rev 12:1-8, 2001
98. Medrano EE: Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: Consequences for proliferation, survival, and metastasis. Oncogene 22:3123-3129, 2003
99. Fukuchi M, Nakajima M, Fukai Y, et al: Increased expression of c-Ski as a co-repressor in transforming growth factor-beta signaling correlates with progression of esophageal squamous cell carcinoma, Int J Cancer 108:818-824, 2004
100. Chinnadurai G: CtBP, an unconventional transcriptional co-repressor in development and oncogenesis. Mol Cell 9:213-224, 2002
101. Ferreira R, Naguibneva I, Pritchard LL, et al: The Rb/chromatin connection and epigenetic control: Opinion. Oncogene 20:3128-3133, 2001
102. Sherr CJ: Principles of tumor suppression. Cell 116:235-246, 2004
103. Reisman DN, Sciarrotta J, Wang W, et al: Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 63:560-566, 2003
104. Fujita N, Jaye DL, Kajita M, et al: MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113:207-219, 2003
105. Bowen NJ, Fujita N, Kajita M, et al: Mi-2/ NuRD: Multiple complexes for many purposes. Biochim Biophys Acta 1677:52-57, 2004
106. Melnick A: Predicting the effect of transcription therapy in hematologic malignancies. Leukemia: in press
107. Avvisati G, Tallman MS: All-trans retinoic acid in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 16:419-432, 2003
108. Schwarze SR, Hruska KA, Dowdy SF: Protein transduction: Unrestricted delivery into all cells? Trends Cell Biol 10:290-295, 2000
109. Wadia JS, Stan RV, Dowdy SF: Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10:310-315, 2004
110. Mourez M, Collier RJ: Use of phage display and polyvalency to design inhibitors of protein-protein interactions. Methods Mol Biol 261:213-228, 2004
111. Crawford M, Woodman R, Ko Ferrigno P: Peptide aptamers: Tools for biology and drug discovery. Brief Funct Genomic Proteomic 2:72-79, 2003
112. Xi S, Gooding WE, Grandis JR: In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: Implications for cancer therapy. Oncogene 24:970-979, 2005
113. Jamieson AC, Miller JC, Pabo CO: Drug discovery with engineered zinc-finger proteins. Nat Rev Drug Discov 2:361-368, 2003
114. Reid GK, Besterman JM, MacLeod AR: Selective inhibition of DNA methyltransferase enzymes as a novel strategy for cancer treatment. Curr Opin Mol Ther 4:130-137, 2002
115. Opalinska J, Kalota A, Gewirtz A: Design of antisense oligonucleotides, and short interfering RNA (siRNA) duplexes, targeted to BCL6 mRNA: Towards rational drug development for specific lymphoma Subsets. Blood 102:137a, 2003
116. Gewirtz AM: Myb targeted therapeutics for the treatment of human malignancies. Oncogene 18:3056-3062, 1999
117. Melnick A, Carlile GW, McConnell MJ, et al: AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood 96:3939-3947, 2000
118. Bhalla K: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 10.1200/JCO.2005 .16.600
119. Muthuswami R, Mesner LD, Wang D, et al: Phosphoaminoglycosides inhibit SWI2/ SNF2 family DNA-dependent molecular motor domains. Biochemistry 39:4358-4365, 2000
120. Finnin MS, Donigian JR, Cohen A, et al: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193, 1999
121. Grozinger CM, Schreiber SL: Deacetylase enzymes: Biological functions and the use of small-molecule inhibitors. Chem Biol 9:3-16, 2002
122. Bitterman KJ, Andersen RM, Cohen HY, et al: Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277: 45099-45107, 2002
123. Kaanders JH, Bussink J, van der Kogel AJ: ARCON: A novel biology-based approach in radiotherapy. Lancet Oncol 3:728-737, 2002
124. Grozinger CM, Chao ED, Blackwell HE, et al: Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 276:38837-38843, 2001
125. Bedalov A, Gatbonton T, Irvine WP, et al: Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A 98:15113-15118, 2001
126. Fournel M, Trachy-Bourget MC, Van PT, et al: Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res 62:4325-4330, 2002
127. Mariadason JM, Corner GA, Augenlicht LH: Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: Comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60:4561-4572, 2000
128. Delia Ragione F, Criniti V, Della Pietra V, et al: Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett 499:199-204, 2001
129. Richon VM, Sandhoff TW, Rifkind RA, et al: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97:10014-10019, 2000
130. Grant S, Dent P: Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors. Cell Cycle 1:383-388, 2002
131. Luo J, Su F, Chen D, et al: Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408:377-381, 2000
132. Qiu L, Burgess A, Fairlie DP, et al: Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11:2069-2083, 2000
133. Nimmanapalli R, Fuino L, Bali P, et al: Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63:5126-5135, 2003
134. Yuan PX, Huang LD, Jiang YM, et al: The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 276:31674-31683, 2001
135. Richon VM, Emiliani S, Verdin E, et al: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 95:3003-3007, 1998
136. Egger G, Liang G, Aparicio A, et al: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463, 2004
137. Silverman LR, Demakos EP, Peterson BL, et al: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440, 2002
138. Wijermans P, Lubbert M, Verhoef G, et al: Low-dose 5-aza-2'- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18:956-962, 2000
139. Daskalakis M, Nguyen TT, Nguyen C, et al: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100:2957-2964, 2002
140. Cinder GD, Whitters MJ, Pohlman JK: Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. Proc Natl Acad Sci U S A 81:3954-3958, 1984
141. Schneider-Stock R, Diab-Assef M, Rohrbeck A, et al: 5-aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. J Pharmacol Exp Ther 312:525-536, 2005
142. Best JL, Amezcua CA, Mayr B, et al: Identification of small-molecule antagonists that inhibit an activator:co-activator interaction. Proc Natl Acad Sci U S A 101:17622-17627, 2004
143. Wong A, Sakamoto KM: Granulocyte-macrophage colony-stimulating factor induces the transcriptional activation of egr-1 through a protein kinase A-independent signaling pathway. J Biol Chem 270:30271-30273, 1995
144. Crans-Vargas HN, Landaw EM, Bhatia S, et al: Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia. Blood 99:2617-2619, 2002